| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536352 | Vaccine | 2017 | 6 Pages |
Abstract
Based on available data, using high-dose influenza vaccine or RIV in middle-aged, high-risk patients may be an economically favorable vaccination strategy with public health benefits. Clinical trials of these vaccines in this population may be warranted.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jonathan M. Raviotta, Kenneth J. Smith, Jay DePasse, Shawn T. Brown, Eunha Shim, Mary Patricia Nowalk, Angela Wateska, Glenson S. France, Richard K. Zimmerman,